OTCMKTS:EPRSQ - Epirus Biopharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0016 0.00 (0.00 %) (As of 03/22/2019 04:00 PM ET)Previous Close$0.0016Today's Range$0.0016 - $0.001652-Week Range$0.0001 - $0.0071Volume11,437 shsAverage Volume3,513 shsMarket Capitalization$40,000.00P/E RatioN/ADividend YieldN/ABeta9.49 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. Receive EPRSQ News and Ratings via Email Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EPRSQ Previous SymbolNASDAQ:EPRS CUSIPN/A CIK1135906 Webwww.epirusbiopharma.com Phone617-600-3497Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$40,000.00 Next Earnings DateN/A OptionableNot Optionable Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions What is Epirus Biopharmaceuticals' stock symbol? Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ." How were Epirus Biopharmaceuticals' earnings last quarter? Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) released its quarterly earnings data on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.20) by $0.32. View Epirus Biopharmaceuticals' Earnings History. Has Epirus Biopharmaceuticals been receiving favorable news coverage? Press coverage about EPRSQ stock has trended somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epirus Biopharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. Who are some of Epirus Biopharmaceuticals' key competitors? Some companies that are related to Epirus Biopharmaceuticals include Orexigen Therapeutics (OREXQ), Immune Pharmaceuticals (IMNP), Inspyr Therapeutics (NSPX), Poniard Pharmaceuticals (PARD), Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Auris Medical (EARS), Bioblast Pharma (ORPN), Bohai Pharmaceuticals Group (BOPH), CannTrust (CNTTF), Cardiome Pharma (CRME), Concordia International (CXRXD) and Concordia International (CXRX). What other stocks do shareholders of Epirus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epirus Biopharmaceuticals investors own include Geron (GERN), GTX (gtxi), SLS International (SLS), Arena Pharmaceuticals (ARNA), Phibro Animal Health (PAHC), Zynga (ZNGA), Repros Therapeutics (RPRX), Molecular Templates (MTEM), Rexahn Pharmaceuticals (RNN) and Ariad Pharmaceuticals (ARIA). Who are Epirus Biopharmaceuticals' key executives? Epirus Biopharmaceuticals' management team includes the folowing people: Mr. Jeff Kagy, VP of HR & Admin.Jason Yap, Head of Global Regulatory Affairs and Sr. DirectorDr. Louis Boon, Head of CLG, Bioassay & Process Devel.Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PDDr. Bram Bout Ph.D., Head of Epirus (Netherlands) B.V. How do I buy shares of Epirus Biopharmaceuticals? Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Epirus Biopharmaceuticals' stock price today? One share of EPRSQ stock can currently be purchased for approximately $0.0016. How big of a company is Epirus Biopharmaceuticals? Epirus Biopharmaceuticals has a market capitalization of $40,000.00. What is Epirus Biopharmaceuticals' official website? The official website for Epirus Biopharmaceuticals is http://www.epirusbiopharma.com. How can I contact Epirus Biopharmaceuticals? Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected] MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 68 (Vote Outperform)Underperform Votes: 62 (Vote Underperform)Total Votes: 130MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?